TriLink Partners With Avantor To Boost Nucleic Acid Supply In EMEA

TriLink BioTechnologies (TriLink®), which operates as a Maravai® LifeSciences company providing life sciences services, has announced the partnership with Avantor Inc., a leading supplier of mission-critical products and services to customers in the life sciences and advanced technology industries, to expand the availability of its innovative nucleic acid products to customers across Europe, Middle East, and Africa (EMEA). The distribution deal should facilitate faster product procurement by European customers while simultaneously streamlining ordering processes.

TriLink operates as an industry-leading organization that specializes in developing and producing nucleic acid products for more than 25 years to push forward mRNA-based therapeutic progress. This agreement enhances product accessibility in EMEA, so European customers can obtain CleanCap® cap analogues (co-transcriptional mRNA caps) alongside catalogue mRNAs and greater than 150 unmodified and modified nucleotides and CleanScribe® RNA Polymerase high-performance IVT enzymes that can serve RUO and GMP-grade applications. TriLink products will be available through VWR’s eCommerce platform, MarketSource.

“This partnership marks an important step in expanding access to our cutting-edge nucleic acid technologies across Europe. By collaborating with a trusted partner like Avantor and leveraging their unmatched distribution network, we can better serve the region’s growing demand for innovative solutions and support the advancement of life-changing therapeutic research,” said Becky Buzzeo, Chief Commercial Officer at TriLink. 

The mission of TriLink centres on nucleic acid therapeutic advancement through CDMO services and high-quality technology and chemistry delivery to customers for vaccine and diagnostic development. The company's mRNA capping analogues now extend to their award-winning CleanCap® M6 as well as raw material nucleotides with other IVT enzymes, including T7 RNA polymerase provided alongside advanced scale-up facilities and unmatched expertise for mRNA and oligonucleotide and enzyme production.